Poster Presentations Session I
Poster Presentations Session I Monday, June 2, 2014
POSTERS SET-UP: 8:15 AM - 8:30 AM
POSTERS DISPLAY HOURS: 8:30 AM - 2:15 PM
POSTER AUTHOR DISCUSSION: 1:15 PM - 2:15 PM
POSTERS DISMANTLE: 2:15 PM


Poster display locations are shown below the poster codes
HEALTH CARE USE & POLICY STUDIES - Consumer Role in Health Care
PHP1
A1
EFFECT OF INVOLVEMENT ON INFORMATION PROCESSING FROM OVER-THE-COUNTER DRUG FACTS PANEL
Bhansali AH, Sansgiry SS
University of Houston, Houston, TX, USA

PHP2
A2
ICD-10 IMPLEMENTATION IN SAUDI ARABIA: CHALLENGES AND OPPORTUNITIES! E-HEALTH IS TRANSFORMING MEDICAL RECORDS TO HEALTH INFORMATION MANAGEMENT!
Albishi HA
Ministry of Health, RIYADH, Saudi Arabia

PHP3
A3
IS FDA'S BREAKTHROUGH THERAPY DESIGNATION A GAME-CHANGING TREND FOR PATIENTS AND PAYERS?
Aggarwal S1, Topaloglu H2
1Novel Health Strategies, Bethesda, MD, USA, 2NOVEL Health Strategies, Chevy Chase, MD, USA

PHP4
A4
4 YOUR KIDS CARE: REDUCING NON-EMERGENT HOSPITALIZATION IN A MEDICAID PEDIATRIC POPULATION THROUGH HANDS-ON TRAINING AND PARENT/CAREGIVER EDUCATION
Grant M, Honeywell A, Dinsmore S, Keleti D, Michael KE, Tan-Torres S, Higgins YL
AmeriHealth Caritas Family of Companies, Philadelphia, PA, USA

PHP5
A5
ROLE OF PATIENT INPUT IN THE CEDAC DRUG REIMBURSEMENT DECISION MAKING PROCESS
Dionne P, Weicker S, Remple V, Tran T
Pfizer Canada, Kirkland, QC, Canada

HEALTH CARE USE & POLICY STUDIES - Disease Management
PHP6
A6
STUDY OF THE SANITARY GEOGRAPHY OF COLOMBIA: A BIG DATA APPROACH
Paez GN, Jaramillo LF, Franco C
Ministry of Health and Social Protection, Bogota, Colombia

HEALTH CARE USE & POLICY STUDIES - Drug/Device/Diagnostic Use & Policy
PHP7
A7
UNDERSTANDING STAKEHOLDER PERSPECTIVES ON MEDICARE'S COVERAGE WITH EVIDENCE DEVELOPMENT (CED) POLICY
Gaffney J, Liow C, Walsh EM, Williams R
Avalere Health LLC, Washington, DC, USA

PHP8
A8
A LONG WAR BEGINS: BIOSIMILARS VERSUS PATENTED BIOLOGICS - A RETROSPECTIVE ANALYSIS OF THE EU-5 AND JAPANESE ERYTHROPOETINS MARKETS
Bocquet F1, Paubel P2, Fusier I3, Cordonnier A4, Le Pen C5, Sinègre M6
1Dauphine University, Paris, France, 2Paris Descartes University, Paris, France, 3General Agency of Equipment and Health Products (AGEPS), PUBLIC WELFARE HOSPITAL OF PARIS (AP-HP), Paris, France, 4General Agency of Equipment and Health Products (AGEPS), AP-HP, Paris, France, 5Université Paris Dauphine, PARIS, France, 6General Agency of Equipment and Health Products (AGEPS), PUBLIC WELFARE HOSPITAL OF PARIS (AP-HP), PARIS, France

PHP9
A9
MEDICAL DEVICES IN JAPAN - A MARKET ACCESS LABYRINTH?
Sealey S1, Edathodu A1, Mukku SR2
1Access Partnership, London, UK, 2The Access Partnership, London, UK

PHP10
A10
PRICE DYNAMICS OF EXTERNAL REFERENCE PRICING-BASED SYSTEMS IN EUROPE
Rémuzat C1, Vataire A1, Urbinati D2, Kornfeld A1, Toumi M3
1Creativ-Ceutical, Paris, France, 2Creativ-Ceutical, Luxembourg, Luxembourg, 3University Claude Bernard Lyon 1, Lyon, France

PHP11
A11
TIME LAGS FROM FDA DRUG APPROVAL TO PUBLICATION OF COST-UTILITY ANALYSIS
Thorat T, Chambers JD, Neumann PJ
Tufts Medical Center, Boston, MA, USA

PHP12
A12
THE TREND OF PRICE LEVEL FOR ANTI-INFECTIVE DRUGS IN CHINA: AN EMPIRICAL STUDY BASED ON MULTIPLE INDEX METHODS
Ma FF, Wu J, Zhao MY
Tianjin University, Tianjin, China

PHP13
A13
PERFORMANCE EVALUATION OF THE ESSENTIAL MEDICINES SYSTEM IN CHINA BASED ON DATA ENVELOPMENT ANALYSIS: A CASE STUDY IN SICHUAN PROVINCE
HU M1, Liao W1, Yang L2, Lin T1
1Sichuan University, Chengdu, China, 2West China Hospital, Sichuan University, Chengdu, China

PHP14
A14
DIVERGENT EVIDENCE REQUIREMENTS COMPARING THE AUTHORIZATION AND REIMBURSEMENT PROCESSES OF HIGH-RISK MEDICAL DEVICES - THE EUROPEAN SITUATION
Krueger LJ1, Evers SM2, Hiligsmann M2, Wild C3
1Maastricht University, Heidelberg, Germany, 2Maastricht University, Maastricht, The Netherlands, 3Ludwig-Boltzmann Institute for Health Technology Assessment, Vienna, Austria

PHP15
A15
OVERVIEW OF EXTERNAL REFERENCE PRICING SYSTEMS IN EUROPE
Rémuzat C1, Urbinati D2, Roïz J3, Kornfeld A1, Toumi M4
1Creativ-Ceutical, Paris, France, 2Creativ-Ceutical, Luxembourg, Luxembourg, 3Creativ-Ceutical, London, UK, 4University Claude Bernard Lyon 1, Lyon, France

PHP16
A16
THE ANALYSIS OF THE DRUG REIMBURSEMENT DECISIONS BEFORE AND AFTER THE POSITIVE LIST SYSTEM IN SOUTH KOREA
Hong J1, Jang S1, Yang B1, Lee H1, Kwon H2, Park M3, Bae EY4
1Seoul National University, Seoul, South Korea, 2Institute of Health and Environment, seoul, South Korea, 3Health Insurance Review and Assessment Service, Seoul, South Korea, 4Gyeongsang National University, Jinju, South Korea

PHP17
B1
ECONOMIC EVALUATION: A CHALLENGE IN INCORPORATING NEW HEALTH TECHNOLOGIES TO THE BRAZILIAN PUBLIC HEALTH SYSTEM (SUS)
Torres ID, Mega TP, Vidal ÁT, Freitas PG, Santos VC, Petramale C
Brazilian Ministry of Health, Brasília-DF, Brazil

PHP18
WITHDRAWN

PHP19
B2
PROGRESS IN PERSONALIZED MEDICINE IS SLOWER THAN SOME HAD EXPECTED, PARTLY BECAUSE OF THE SCIENCE AND PARTLY BECAUSE OF INSUFFICIENT ECONOMIC INCENTIVES, PARTICULARLY FOR INVESTING IN MOLECULAR DIAGNOSTICS (MDX)
Mallinson M
Access Partnership, London, UK

PHP20
B3
ASSESSMENT OF PHARMACEUTICAL PRODUCTS APPROVED BY THE US FDA AND REGISTERED IN PERU
Araujo L, Balkhi B, Seoane-Vazquez E
MCPHS University, Boston, MA, USA

PHP21
WITHDRAWN

PHP22
B4
EVALUATING CRITICISM OF THE FDA ACCELERATED APPROVAL PATHWAY - EMA EVALUATION OF DRUGS THAT HAVE BEEN WITHDRAWN FOLLOWING ACCELERATED APPROVAL BY THE FDA
Macaulay R
HERON Commercialization, London, UK

PHP23
B5
ESTIMATION OF CHANGE IN PRESCRIPTION DRUG EXPENDITURES ON THE REFERENCE PRICING SYSTEM IN SOUTH KOREA
Heo JH1, Rascati KL2, Lee E3
1University of Texas at Austin, Austin, TX, USA, 2The University of Texas at Austin, College of Pharmacy, Austin, TX, USA, 3Sungkyunkwan University, Suwon-si, Gyeonggi-do, South Korea

PHP24
B6
PHARMACEUTICAL COMPANIES PRICING STRATEGIES AFTER GENERIC ENTRY INTO THE NEW ZEALAND MARKET
Rodriguez-Monguio R1, Seoane-Vazquez E2
1University of Massachusetts, Amherst, MA, USA, 2International Center for Pharmaceutical Economics and Policy, Massachusetts College of Pharmacy and Health Sciences, Boston, MA, USA

PHP25
B7
DIFFERENTIAL EFFECTS OF TWO PHARMACEUTICAL COST CONTAINMENT POLICIES ON OUTPATIENT PRESCRIPTION DRUG EXPENDITURES IN KOREA
Park S1, Han E2, Kim N1, Chae S1, Ryu C3
1Korea Institute for Health and Social Affairs, Seoul, South Korea, 2Gachon University, Incheon, South Korea, 3Baxter Incorporated, South Korea

PHP26
B8
INSIGHTS IN EUROPEAN DRUG SHORTAGES: A SURVEY OF HOSPITAL PHARMACISTS
Pauwels K, Simoens S, Casteels M, Huys I
KU Leuven, Leuven, Belgium

PHP27
B9
AN UPDATE ON HOW NICE MANAGE OFF-LABEL COMPARATORS
Kusel J1, Steeves S1, Maruszczak M1, Pettit LJ1, Taylor D2
1Costello Medical Consulting Ltd., Cambridge, UK, 2University College London, London, UK

PHP28
B10
POINT OF CARE TESTS: THE LONG AND WINDING ROAD TO REIMBURSEMENT IN THE US AND CANADA
Hogue S1, Brogan A1, Fernandez M2, Hong L3
1RTI-Health Solutions, Research Triangle Park, NC, USA, 2RTI Health Solutions, RTP, NC, USA, 3University of North Carolina - Gillings School of Global Public Health, Chapel Hill, NC, USA

PHP29
B11
REAL LIFE IMPACT OF EXTERNAL REFERENCE PRICING IN EUROPE USING A SIMULATION MODEL
Rémuzat C1, Vataire A1, Kornfeld A1, Aballea S1, Toumi M2
1Creativ-Ceutical, Paris, France, 2University Claude Bernard Lyon 1, Lyon, France

PHP30
B12
COMPARISON OF PREDICTABILITY OF MEDICAL DEVICE REVIEW PERIOD IN THE UNITED STATES AND JAPAN
Umei A, Fujimura S
Tokyo Institute of Technology, Tokyo, Japan

PHP31
B13
GAP BETWEEN PAYERS AND REGULATORS MANAGEMENT OF RISK PREVENTS AND DELAYS PATIENT ACCESS TO NEW THERAPY
Zard J1, Kornfeld A1, Rémuzat C1, Toumi M2
1Creativ-Ceutical, Paris, France, 2University Claude Bernard Lyon 1, Lyon, France

PHP32
B14
COMMUNITY PHARMACIST CHARACTERISTICS ASSOCIATED WITH USE OF A PRESCRIPTION DRUG MONITORING PROGRAM
Wixson SE, Blumenschein K, Goodin AJ, Talbert J, Freeman PR
University of Kentucky, Lexington, KY, USA

PHP33
B15
FIRST EVALUATION OF COLOMBIAN'S EXTERNAL REFERENCE PRICING SYSTEM
Andia T, Gaviria A, Gomez C, Jaramillo LF, Marquez S, Rodríguez I, Vaca C
Ministry of Health and Social Protection, Bogota, Colombia

PHP34
B16
INTERACTION OF ROSMARINUS OFFICINALIS L. ESSENTIAL OIL WITH DIAZEPAM AND PENTOBARBITAL IN EXPERIMENTAL ANIMALS
Milanovic I1, Raskovic A2, Gluvnja I2, Stilinovic N2, Mikov M3
1High medical School of Professional Skills Belgrade, Zemun, Belgrade, Serbia and Montenegro, 2University of Novi Sad,Faculty of Medicine, Novi Sad, Serbia and Montenegro, 3University of Novi Sad, Faculty of Medicine, Novi Sad, Serbia and Montenegro

PHP35
C1
USE OF HIGH ALERT CHINESE MEDICATIONS IN TAIWAN: A RETROSPECTIVE POPULATION-BASED COHORT STUDY
Lin H1, Tsai H1, Tsai C2, Hsieh Y2, Lin S2, Lin W2, Jan S2, Tu C2, Chang K2
1China Medical University, Taichung, Taiwan, 2China Medical University Hospital, Taichung, Taiwan

PHP36
C2
2-YEAR FOLLOW-UP OF PERSISTENCE OF INFUSION AND SELF-ADMINISTERED BIOLOGICS ACROSS INDICATIONS
Kozma C1, Paris A2, Ingham M3
1CK Consulting, Saint Helena Island, SC, USA, 2Vigilytics, Victor, NY, USA, 3Janssen Scientific Affairs, LLC, Horsham, PA, USA

PHP37
C3
EXAMINING THE EFFECT OF PHARMACISTS' VISITS TO HOMEBOUND PATIENTS ON THE ELIMINATION OF UNUSED DRUGS – A REPORT FROM A HEALTH AND LABOUR SCIENCES STUDY –
Onda M1, Kasuga M1, Fujii S1, Nanaumi Y2, Imai H3
1Osaka University of Pharmaceutical Sciences, Takatsuki, Osaka, Japan, 2Advanced Pharma Research office, Nara, Japan, 3National Institute of Public Health, Wako, Saitama, Japan

PHP38
WITHDRAWN

PHP39
C4
RISK FACTORS OF ADVERSE DRUG REACTION–RELATED HOSPITALIZATIONS AMONG SENIORS, 2006 TO 2011
Proulx J
CIHI, Ottawa, ON, Canada

PHP40
C5
PROFILING HEALTHCARE UTILIZATION OF ELDERLY VS. DISABLED MEDICARE DUAL ELIGIBLES: DIFFERENT STROKES FOR DIFFERENT FOLKS
Doshi JA1, Li P1, Subedi P2, Davis-Cerone M2
1University of Pennsylvania, Philadelphia, PA, USA, 2Pfizer Pharmaceuticals, Inc., New York, NY, USA

PHP41
C6
A COLLABORATIVE APPROACH TO PROGRAM DECISION MAKING: A RANDOMIZED TRIAL OF A PBM VENDOR SOLUTION
Smith-McLallen A1, Zhang B2, Estes E1, Buss W2
1Independence Blue Cross, Philadelphia, PA, USA, 2Catamaran, Schaumburg, IL, USA

PHP42
C7
TRENDS IN MEDICAID FEE-FOR-SERVICE OUTPATIENT DRUG UTILIZATION, EXPENDITURES AND PHARMACY REIMBURSEMENT RATES (2010-2012)
Balkhi B1, Alshehri A1, Szeinbach SL2, Seoane-Vazquez E1
1International Center for Pharmaceutical Economics and Policy, Massachusetts College of Pharmacy and Health Sciences, Boston, MA, USA, 2Ohio State University, Columbus, OH, USA

PHP43
C8
PREVALENCE OF PRESCRIPTION MEDICATION USE NOT CAPTURED BY PRESCRIPTION CLAIMS DATABASES
Electricwala BS, Carroll NV
Virginia Commonwealth University, Richmond, VA, USA

PHP44
C9
IMPACT OF DRUG REIMBURSEMENT MODALITIES ON TREATMENT ADHERENCE IN PATIENTS COVERED BY PRIVATE DRUG INSURANCE
Després F1, Forget A1, Kettani FZ1, Blais L2
1Université de Montréal, Montreal, QC, Canada, 2University of Montreal, Montreal, QC, Canada

HEALTH CARE USE & POLICY STUDIES - Equity and Access
PHP45
C10
DIFFERENCE BETWEEN USA AND EU AUTHORISATION TIMELINES AND TIME TO REIMBURSEMENT IN THE EU5
Sun D1, Beckerman R2
1CBPartners, New York City, NY, USA, 2CBPartners, New York, NY, USA

PHP46
C11
SOCIOECONOMIC AND HEALTH DETERMINANTS ASSOCIATED WITH THE USE OF THE AMBULATORY AND HOSPITAL CARE SERVICES AMONG THE MEXICAN POPULATION
Uc-Coyoc RO, Pérez-Reynaud AG, Coello-Reyes LA, Rodriguez-Díaz Ponce MA
Instituto Mexicano del Seguro Social, D.F, Mexico

PHP47
C12
RAJASTHAN'S UNIVERSAL HEALTHCARE PLAN WITH FREE DISTRIBUTION OF QUALITY MEDICINES THROUGH COST MINIMIZATION
Gurbani NK1, Sharma S2
1Institute of Health Management Research (IIHMR), JAIPUR, India, 2Rajasthan Medical & Services Corporation, JAIPUR, India

PHP48
C13
REAL-WORLD CLINICAL EVIDENCE DEVELOPMENT: AN ANALYSIS OF RELEVANT INTERNATIONAL MODELS FOR THE POTENTIAL IMPLEMENTATION OF SUCH A PROGRAM IN QUEBEC
Bibeau J1, Savoie M2, Lachaine J1
1University of Montreal, Montreal, QC, Canada, 2Montreal InVivo, Montreal, QC, Canada

HEALTH CARE USE & POLICY STUDIES - Formulary Development
PHP49
C14
USE OF ECONOMIC EVIDENCE TO INFORM DRUG REIMBURSEMENT DECISION MAKING: THE CASE FOR ONTARIO
Syed S, Agarwal A, Xie F
McMaster University, Hamilton, ON, Canada

PHP50
C15
ACADEMY OF MANAGED CARE PHARMACY (AMCP) DOSSIERS: USE IN HEALTH CARE DECISION MAKING
Hogue S1, Brogan A1, Earnshaw S2, Khan S1, Nelsen S1
1RTI-Health Solutions, Research Triangle Park, NC, USA, 2RTI Health Solutions, Research Triangle Park, NC, USA

PHP51
C16
IMPACT OF EARLY HEALTH TECHNOLOGY ADVICE ON CLINICAL DEVELOPMENT PROGRAMS
Patel MB1, Lee S2, Moran DM3, Rastogi S4
1Sanofi, Bridgewater, NJ, USA, 2, Fort Lee, NJ, USA, 3Sanofi, Brier, WA, USA, 4Self employed, Princeton, NJ, USA

HEALTH CARE USE & POLICY STUDIES - Health Care Costs & Management
PHP52
D1
SOURCES OF SPENDING VARIATION IN PROFESSIONAL SERVICES AMONG TEXAS HOSPITAL REFERRAL REGIONS: AN ANALYSIS OF PRIVATE INSURANCE POPULATION
Parikh R1, Taychakhoonavudh S1, White C2, Franzini L1
1The University of Texas School of Public Health, Houston, TX, USA, 2RAND Corporation, Arlington, VA, USA

PHP53
D2
ANALYSIS OF AVERAGE MANUFACTURER PRICES OF NEW DRUGS APPROVED IN THE US (1990-2012)
Alshehri N1, Alqahatani S2, Alghamdi AA1, Alharbi AM2, Al-Mutairi RD2, Alotaibi A3, Alshahrani AM4, Alsumali A2, Badawoud EM2, Bin Sawad A2, Turkistani FA2, Seoane-Vazquez E2, Rodriguez-Monguio R5
1Massachusetts College of Pharmacy and Health Sciences, Boston, MA, USA, 2International Center for Pharmaceutical Economics and Policy, Massachusetts College of Pharmacy and Health Sciences, Boston, MA, USA, 3Umm Al-Qura University, Mecca, Saudi Arabia, 4Massachusetts College of Pharmacy and Health Sciences University, Boston, MA, USA, 5University of Massachusetts Amherst, Amherst, MA, USA

PHP54
D3
A COMPARISON OF THE MEDICARE AVERAGE SALES PRICE AND THE AVERAGE WHOLESALER PRICE
Abraham P1, Gholmie J1, Rodriguez-Monguio R2, Seoane-Vazquez E3
1Massachusetts College of Pharmacy and Health Sciences, Boston, MA, USA, 2University of Massachusetts, Amherst, MA, USA, 3International Center for Pharmaceutical Economics and Policy, Massachusetts College of Pharmacy and Health Sciences, Boston, MA, USA

PHP55
WITHDRAWN

PHP56
D4
OUT OF POCKET EXPENDITURE ON AMBULATORY HEALTH SERVICES AMONG PATIENTS AT THE MEXICAN INSTITUTE OF SOCIAL SECURITY (IMSS)
Uc-Coyoc RO, Coello-Reyes LA, Pérez-Reynaud AG, Rodriguez-Díaz Ponce MA
Instituto Mexicano del Seguro Social, D.F, Mexico

PHP57
D5
IMPACT OF ADVANCED THERAPY MEDICINAL PRODUCTS COST ON PUBLIC HEALTH CARE BUDGETS
Toumi M1, Kornfeld A2, Charaf A3
1University Claude Bernard Lyon 1, Lyon, France, 2Creativ-Ceutical, Paris, France, 3Creativ-Ceutical, Tunis, Tunisia

PHP58
D6
COST IMPLICATION OF IRRATIONAL DRUG PRESCRIPTION UNDER THE NATIONAL HEALTH INSURANCE SCHEME IN RURAL GHANA
Apanga S1, Chirawurah D1, Kudiabor C2, Adda J1, Adoesom JA3
1university for development studies, tamale, Ghana, 2kintampo municipal hospital, kintampo, Ghana, 3kintampo municipal mutual health insurance scheme, kintampo, Ghana

PHP59
D7
WITHDRAWN

PHP60
D8
MEDICATION USE SURVEY OF INPATIENTS WITH BASIC HEALTH INSURANCE FROM 2010 TO 2011 IN CHINA
Xiong X1, Li J1, Du F2, Zhang J1, Ma Y1
1China Health Insurance Research Association, Beijing, China, 2Beijing Brainpower Pharma Consulting Co. Ltd., Beijing, China

PHP61
D9
THE PROMISE OF BIG DATA – DOES THE FINANCIAL INVESTMENT PROVIDE A RETURN ON INVESTMENT FOR SMALL TO MID-SIZE MANUFACTURERS?
Gavaghan M1, Garfield S1, Armstrong S2
1GfK Market Access, Wayland, MA, USA, 2GfK, Wayland, MA, USA

PHP62
D10
A COMPARATIVE ANALYSIS OF PRIVATE HEALTH INSURANCE SYSTEMS IN USA, SOUTH AFRICA AND TURKEY
Seyhun O1, Can H2, Erdol S3
1MEDTRONIC INC, Istanbul, Turkey, 2Medtronic, Istanbul, Turkey, 3Medtronic, Inc., Istanbul, Turkey

PHP63
D11
WITHDRAWN

PHP64
D12
ENGAGEMENT IN AND FINANCIAL PEROFRMANCE OF A TRANSITIONAL CASE MANAGEMENT PROGRAM AMONG MEMBERS ENROLLED IN ADMINISTRATIVE-SERVICES-ONLY INSURANCE ARRANGEMENTS
Bhattarai G1, Ozminkowski R2, Den Hartog KS3
1OptumHealth, MINNEAPOLIS, MN, USA, 2OptumHealth, ANN ARBOR, MI, USA, 3OptumHealth, Golden Valley, MN, USA

PHP65
D13
A VALUATION SYSTEM FOR PRIVATE LIFE INSURANCE AND ANNUITY INSURANCE UNDER TAIWAN'S NATIONAL HEALTH INSURANCE SYSTEM
Hsu WW1, Wu Y1, Hsiao F2
1National Taiwan Ocean University, Keelung, Taiwan, 2National Taiwan University, Taipei, Taiwan

PHP66
D14
THE EFFECT OF MASSACHUSETTS HEALTH CARE REFORM ON HOSPITAL INPATIENT USE
Marder W1, Lenhart GM2, Karaca Z3, Wier LM2, Wong H3
1| Truven Health Analytics, Cambridge, MA, USA, 2Truven Health Analytics, Cambridge, MA, USA, 3Agency for Healthcare Research and Quality (AHRQ), Rockville, MD, USA

PHP67
D15
SYSTEMATIC REVIEW OF COST EFFECTIVENESS OF TOP SELLING PRODUCTS
Aggarwal S1, Topaloglu H2
1Novel Health Strategies, Bethesda, MD, USA, 2NOVEL Health Strategies, Chevy Chase, MD, USA

PHP68
D16
HOW ARE BIOSIMILAR MEDICINES APPRAISED AS HEALTH TECHNOLOGIES? AN EVALUATION OF APPRAISAL PROCESSES IN MULTIPLE COUNTRIES
Smith TA, de Silva SU, Bending MW
Mapi, London, UK

PHP69
E1
THE ROLE OF PATIENT-PHYSICIAN COMMUNICATION ON HEALTHCARE COSTS
Karaca Z, Wong H
Agency for Healthcare Research and Quality (AHRQ), Rockville, MD, USA

PHP70
E2
DO MEDICARE ADVANTAGE ENROLLEES VISIT HIGH-COST HOSPITALS?
Karaca Z1, Wong H1, Stensland J2
1Agency for Healthcare Research and Quality (AHRQ), Rockville, MD, USA, 2Medicare Payment Advisory Commission, Washington, DC, USA

PHP71
E3
ACCESS TO SEXUAL REPRODUCTIVE HEALTH RIGHTS INFORMATION AMONG THE YOUTH: A CASE OF GUCHA SOUTH DISTRICT, KISII COUNTY-KENYA
Mogere DM1, Obutu CJ2
1Great Lakes University of Kisumu, Kisumu, Kenya, 2Ministry of Health, Kisii, Kenya

PHP72
E4
A QUALITATIVE COMPARISON OF ADMINISTRATIVE DATABASES IN ASIA
Reginald P1, Azmi S1, Verpillat P2, François C3, Milea D4
1Azmi Burhani Consulting, Petaling Jaya, Malaysia, 2Lundbeck SAS, Issy-les-Moulineaux Cedex, France, 3Lundbeck SAS, France, 4Lundbeck Singapore Pte Ltd., Singapore, Singapore

PHP73
E5
TRANSPARENCY IN MEDICAL DEVICES PRICING: INFORMATION THAT HELPS DIFFERENT STAKEHOLDERS IN DECISION MAKING
Pereira RF1, Caldeira TR1, Pereira MR2
1Brazilian Health Surveillance Agency (Anvisa), Brasília, Brazil, 2ANVISA, BRASILIA, Brazil

PHP74
E6
WHAT DRIVES PRIVATE INVESTMENT IN HEALTH ECONOMICS AND OUTCOMES RESEARCH?
Bajaj PS1, Willke RJ2, Sullivan SD1, Garrison LP1
1University of Washington, Seattle, WA, USA, 2Pfizer, Inc., New York, NY, USA

PHP75
E7
UNDERSTANDING ATTITUDES TOWARD PHYSICIAN-NURSE COLLABORATION IN PATIENT-CENTERED MEDICAL HOMES
Coschignano C1, Karagiannis T2, Polenzani L3, Messina E4, Zoli R5, Maio V6
1Casa della Salute, Scandicci, Italy, 2Jefferson School of Population Health, Philadelphia, PA, USA, 3CFSMG Regione Toscana, Prato, Italy, 4CFSMG Regione Toscana, Firenze, Italy, 5CFSMG Regione Toscana, Scandicci, Italy, 6Thomas Jefferson University, Philadelphia, PA, USA

PHP76
WITHDRAWN

PHP77
E8
A COMPARATIVE STUDY ON PATIENT SAFETY CULTURE FOR PHARMACISTS IN JAPAN
Hirose M1, Egami K2, Tsuda Y2, Honda J2, Shima H2
1Shimane University Hospital, Izumo, Japan, 2St. Mary's Hospital, Kurume, Japan

PHP78
E9
FACTORS THAT IMPACT REPORTING OF ADVERSE DRUG EVENTS BY PHARMACISTS: A SYSTEMATIC LITERATURE REVIEW
Arabyat RM1, Raisch DW2
1University of New Mexico, Albuqurque, NM, USA, 2University of New Mexico College of Pharmacy, Albuquerque, NM, USA

PHP79
E10
PATIENTS' EXPECTATIONS AND INTENTIONS TO RECEIVE MEDICATION COUNSELING FROM COMMUNITY PHARMACISTS
Ferries EA, Fleming ML, Hatfield MD, Atreja N, Yucel A, Rane P, Wang X, Sharma M
University of Houston, Houston, TX, USA

PHP80
E11
THE STATE OF THE COMPARATIVE EFFECTIVENESS RESEARCH (CER) ENVIRONMENT: SURVEYS OF STAKEHOLDERS AND INFLUENTIALS
Westrich KD1, Schur C2, Adams A2
1National Pharmaceutical Council, Washington, DC, USA, 2Social & Scientific Systems, Silver Spring, MD, USA

PHP81
E12
SHORTAGES OF DRUGS WITH APPROVED ORPHAN INDICATIONS IN THE US
Felemban D1, Ghazawi K1, Alsheikh M1, Seoane-Vazquez E2, Rodriguez-Monguio R3, Fox ER4, Szeinbach SL5
1Massachusetts College of Pharmacy and Health Sciences, Boston, MA, USA, 2International Center for Pharmaceutical Economics and Policy, Massachusetts College of Pharmacy and Health Sciences, Boston, MA, USA, 3University of Massachusetts Amherst, Amherst, MA, USA, 4University of Utah Hospitals and Clinics, Salt Lake City, UT, USA, Salt Lake City, UT, USA, 5Ohio State University, Columbus, OH, USA

PHP82
E13
GLOBAL SNAPSHOT OF THE ECONOMIC BURDEN OF DISEASE-RELATED MALNUTRITION IN HOSPITALIZED PATIENTS
Sanon M1, Walter E2, Hise-Brown M1, Dovas A1, Bauer M2
1Baxter Healthcare, Deerfield, IL, USA, 2The Institute for Pharmaeconomic research, Vienna, Austria

PHP83
E14
OUTCOMES OF IN-PERSON VERSUS TELEPHONIC MEDICATION THERAPY MANAGEMENT (MTM) SERVICES PROVIDED TO MEDICARE PART D BENEFICIARIES
Mbagwu GI1, Cunningham ML2, Godley PJ3
1Scott & White Health Plan/ The University of Texas at Austin, Temple, TX, USA, 2Scott & White Health Plan, Temple, TX, USA, 3Scott & White Health Plan/Novartis Pharma/The Univ of Texas at Austin, Temple, TX, USA

PHP84
E15
COMPARISON OF TWO AGENTS FOR THE REVERSAL OF NEUROMUSCULAR BLOCKADE: A DISCRETE EVENT SIMULATION MODEL OF OPERATING ROOM EFFICIENCY IN CANADA
Goyette A1, Insinga RP2, Galarneau A1, Maiese EM3
1Merck Canada Inc., Kirkland, QC, Canada, 2Merck & Co. Inc., Upper Gwynedd, PA, USA, 3Merck & Co, Inc., Whitehouse Station, NJ, USA

PHP85
E16
COMBINATION DRUGS: MAKING IT EASY FOR CDR TO SAY "YES"?
Mills F, Siu E, Poinas A, Wyatt G
Wyatt Health Management, Oakville, ON, Canada

PHP86
F1
IMPACT OF THE PAN CANADIAN PRICING ALLIANCE ON TIME TO LISTING IN CANADA
Robertson C, Zhang Y, Bosnic N
IMS Brogan, Ottawa, ON, Canada

PHP87
F2
HEALTH TECHNOLOGY ASSESSMENT IN BRAZIL: A TECHNICAL ANALYSIS
Teich V, Junqueira M, Pepe C, Mussolino F, Vaz P
NewBD/Medinsight - Grupo Resulta, São Paulo, Brazil

PHP88
F3
IS THERE A ROOM FOR NON-ECONOMIC CRITERIA IN THE DECISION MAKING PROCESS IN THE HEALTHCARE SECTOR IN POLAND?
Kolasa K
Department of Pharmacoeconomics, Medical University of Warsaw, Warsaw, Poland

PHP89
F4
A QUALITATIVE ANALYSIS OF NICE TECHNOLOGY APPRAISALS: IDENTIFYING TRENDS AND COMMONALITIES IN RESTRICTED AND NON-RECOMMENDED PHARMACEUTICALS
Cho YP, Dalsania RR
GfK Market Access, New York, NY, USA

PHP90
F5
CONCEPUTALIZING A MODEL TO ASSESS THE IMPACT OF INTERNATIONAL REFERENCE PRICING REFORMS
Robbins S1, Staginnus U2, Dosanjh J1, Gitlin M3
1InnoPeritus, Geneva, Switzerland, 2Endocyte, Zug, Switzerland, 3InnoPeritus, Venice, CA, USA

PHP91
F6
ASSESSING THE QUALITY OF HEALTH ECONOMIC EVALUATIONS ATTACHED TO PRICE APPLICATIONS FOR NEW PHARMACEUTICALS PROPOSED FOR INCLUSION IN THE FINNISH REIMBURSEMENT SYSTEM
Maljanen T, Koskinen H, Tuominen U
The Social Insurance Institution, Helsinki, Finland

PHP92
F7
DISSECTING THE DELAYS: THE IMPACT OF NEW POLICIES AND PRACTICES ON TOTAL TIME TO REIMBURSEMENT IN ONTARIO
Mills F, Siu E, Poinas A, Wyatt G
Wyatt Health Management, Oakville, ON, Canada

PHP93
F8
BENEFIT DESIGN CHANGE IN A COMMERCIALLY INSURED CONTINUOUSLY ENROLLED POPULATION
Su W1, Carlson A1, Hedin C2
1University of Minnesota, Minneapolis, MN, USA, 2Prime Therapeutics, minneapolis, MN, USA

PHP94
F9
ASSESSING LEVELS OF THERAPEUTIC IMPROVEMENT: AN INTERNATIONAL COMPARISON
Mani A, Nelson C, Gibson L, Palmer WN, Hughes A
PDCI MARKET ACCESS, OTTAWA, ON, Canada

PHP95
F10
FACTORS INFLUENCING US PAYER COVERAGE OF ELECTIVE BIOMARKER DIAGNOSTICS
Dandappanavar AS1, Knight JM1, Campbell CM1, Popelar BV1, Jackson JH1, Reeder G2
1Xcenda, LLC, Palm Harbor, FL, USA, 2Xcenda/ University of South Carolina, Columbia, SC, USA

PHP96
F11
NATURE OF ENDPOINTS IN MARKET ACCESS AGREEMENTS
Toumi M1, Zard J2, Rémuzat C2, Ben Abdallah I2, Jaroslawski S3
1University Claude Bernard Lyon 1, Lyon, France, 2Creativ-Ceutical, Paris, France, 3, India

PHP97
F12
CHALLENGES FACED BY DECISION MAKERS FROM MIDDLE INCOME COUNTRIES IN TRANSFERRING PHARMACOECONOMIC DATA AND ANALYSES FROM OTHER JURISDICTIONS
Drummond M1, Augustovski F2, Kalo Z3, Yang B4, Pichon-Riviere A5, Bae EY6, Kamal-Bahl S7
1University of York, Heslington, York, UK, 2Family and Community Medicine Division, Italian Hospital of Buenos Aires, Buenos Aires, Argentina, 3Eotvos Lorand University, Budapest, Hungary, 4Seoul National University, Seoul, South Korea, 5Institute for Clinical Effectiveness and Health Policy (IECS), Buenos Aires, Argentina, 6Gyeongsang National University, Gyeongnam, South Korea, 7Merck and o, Inc, Upper Gwynedd, PA, USA

HEALTH CARE USE & POLICY STUDIES - Health Care Research & Education
PHP98
F13
SHORTCUTTING DRUG DEVELOPMENT: ECONOMIC BENEFITS OF USING GENOME-WIDE ASSOCIATION STUDIES (GWAS) TO REPOSITION EXISTING DRUGS TO OTHER THERAPEUTIC AREAS
Caro JJ1, Richards B2
1Evidera, Lexington, MA, USA, 2Jewish General Hospital, Montreal, QC, Canada

PHP99
F14
EXPLORING AWARENESS AMONG GENERAL PUBLIC TOWARDS ISSUES RELATED TO MEDICATION SAFETY IN QUETTA, PAKISTAN
Jan SU1, Iqbal Q1, Haq N1, Akhtar M2
1University of Balochistan, Quetta, Pakistan, 2The Islamia University of Bahawalpur, Bahawalpur, Pakistan

PHP100
F15
CONTRIBUTION OF HEALTH ECONOMICS & OUTCOMES RESEARCH STUDIES OF COLOMBIA TO ISPOR CONFERENCES
Gutierrez-Ardila MV, Vargas Zea N
Pfizer S.A.S., Bogotá, Colombia

HEALTH CARE USE & POLICY STUDIES - Health Technology Assessment Programs
PHP101
WITHDRAWN

PHP102
F16
HEALTH TECHNOLOGY ASSESSMENT (HTA) ACTIVITY WORLDWIDE DURING 2012 AND 2013: MAIN TRENDS
Skaltsa K1, Heemstra L2, Tao C3, Van Engen A2
1Quintiles Consulting, Barcelona, Spain, 2Quintiles Consulting, Hoofddorp, The Netherlands, 3Quintiles Consulting, Cambridge, MA, USA

PHP103
G1
NEED FOR SUBGROUP COST EFFECTIVENESS ANALYSES FOR HEALTH TECHNOLOGY ASSESSMENTS
Aggarwal S1, Topaloglu H2
1Novel Health Strategies, Bethesda, MD, USA, 2NOVEL Health Strategies, Chevy Chase, MD, USA

PHP104
G2
THE HTA REGULATION ON THE BRAZILIAN HEALTHCARE SYSTEM AND ITS IMPACT ON FEDERAL SPENDING ON HEALTH TECHONOLOGIES SUPPLY THROUGH LAWSUITS
Simabuku E, Chacarolli C, Torres ID, Pereira V, Capucho H, Santos VC, Petramale C
Brazilian Ministry of Health, Brasília-DF, Brazil

PHP105
G3
THE ITALIAN MEDICINES AGENCY EXPERIENCE WITH HTA SCIENTIFIC ADVICE ACTIVITIES: A COMPREHENSIVE ANALYSIS OF THREE YEARS OF NATIONAL AND INTERNATIONAL ACTIVITIES
Siviero PD1, Montilla S2, Sammarco A2, Trotta MP2, Tafuri G2, Pani L3
1Italian Medcines Agency, Rome, Italy, 2Italian Medicines Agency, Rome, Italy, 3Italian Medicines Agency (AIFA), Rome, Italy

PHP106
G4
EXPLORING THE VARIABILITY BETWEEN DISEASE TYPE AND THE PROPORTION OF SUBMISSIONS WITH ICERS HIGHER THAN THE THRESHOLD THAT ARE ACCEPTED BY HTA AGENCIES
Griffiths EA, Walsh SC
PAREXEL, London, UK

PHP107
G5
EXPLORING THE VARIABILITY BETWEEN DISEASE TYPE AND THE PROPORTION OF SUBMISSIONS WITH ICERS LOWER THAN THE THRESHOLD THAT ARE REJECTED BY HTA AGENCIES
Walsh SC, Griffiths EA
PAREXEL, London, UK

PHP108
G6
CONSISTENCY IN REIMBURSEMENT DECISIONS AT CANADIAN HTA AGENCIES: INESSS VS. CDR
Mills F, Poinas A, Siu E, Wyatt G
Wyatt Health Management, Oakville, ON, Canada

PHP109
G7
INTERNATIONAL HTA REFERENCING - A REALITY?
Sealey S1, Edathodu A1, Mukku SR2
1Access Partnership, London, UK, 2The Access Partnership, London, UK

PHP110
G8
WITHDRAWN

PHP111
G9
AN ANALYSIS OF REAL WORLD DATA TRENDS IN GLOBAL HTA MARKETS
Horowicz-Mehler N1, Tao C2, Faulkner EC3, Doyle JJ4
1Quintiles Global Consulting, New York, NY, USA, 2Quintiles Consulting, Cambridge, MA, USA, 3Institute for Pharmacogenomics and Individualized Therapy, Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, NC, USA, 4Quintiles, Hawthorne, NY, USA

PHP112
G10
EVIDENCE-BASED PRACTICE RECOMMENDATIONS: HEALTH QUALITY ONTARIO'S APPROACH
Brener SS, Nikitovic M, Chambers A, Ghazipura M, Schaink AK, Lambrinos AI, Levin L
Health Quality Ontario, Toronto, ON, Canada

HEALTH CARE USE & POLICY STUDIES - Patient Registries & Post-Marketing Studies
PHP113
G11
PERCEIVED BENEFITS AND BARRIERS OF PAYER-MANUFACTURER POST-MARKETING OUTCOMES STUDY COLLABORATIONS
Olvey EL1, Svoboda K2, Coraggio R2, White NP3, Yi D2, del Rosario C2, Malik S2
1NucleusX Market Access, Atlanta, GA, USA, 2Percipient LLC, Somerville, NJ, USA, 3NucleusX Market Access, Altanta, GA, USA

PHP114
G12
ARE PROMOTIONAL STRATEGIES OF LIFESTYLE DRUGS DIFFERENT FROM NON-LIFESTYLE DRUGS? A CONTENT ANALYSIS OF DTC PRINT MEDIA
Shanbhag P1, Kapratwar A1, Nayak R2
1St. Johns University, Fresh Meadows, NY, USA, 2St. John's University, Jamaica, NY, USA

PHP115
G13
OPPORTUNITIES FOR THE FUTURE OF U.S. MEDICAL DEVICE SURVEILLANCE: AN ANALYSIS OF THE JOINT REPLACEMENT REGISTRY (JRR) LANDSCAPE IN THE UNITED STATES
Pratt KJ, Song KM, Mitchell K
Avalere Health LLC, Washington, DC, USA

HEALTH CARE USE & POLICY STUDIES - Prescribing Behavior & Treatment Guidelines
PHP116
G14
USE OF GLASGOW ANTIMICROBIAL AUDIT TOOL (GAAT) TO ASSESS ANTIMICROBIAL USE IN THE ICUS OF AN INDIAN PUBLIC TEACHING HOSPITAL
Gudapati BN1, Tiwari P2, Gombar S3, D'cruz S4, Sachdev A4
1National Institute of Pharmaceutical Education and Research, Mohali, India, 2National Institute of Pharmaceutical Education and Research (NIPER), S.A.S Nagar, India, 3Government Medical College & Hospital, Chandigarh, India, 4Government Medical College and Hospital, Chandigarh, India

PHP117
G15
FACTORS PREDICTING MEDICATION OVERSUPPLY IN THAILAND: A MIXED MODEL REGRESSION ANALYSIS
Dilokthornsakul P1, Chaiyakunapruk N2, Nimpitakpong P3, Jeanpeerapong N4, Jampachaisri K5, Lee TA6
1Department of Pharmacy Practice, Faculty of Pharmaceutical Sciences, Naresuan University, Phitsanulok, Thailand, 2Monash University Malaysia, Selangor, Malaysia, 3Center of Pharmaceutical Outcomes Research, Naresuan University, Muang, Phitsanulok, Thailand, 4Buddhachinaraj Hospital, Muang, Thailand, 5Naresuan University, Muang, Phitsanulok, Thailand, 6University of Illinois at Chicago, Chicago, IL, USA

PHP118
G16
TRENDS IN USE OF ECONOMIC EVIDENCE BY CLINICAL GUIDELINES
Aggarwal S, McGrane M
Novel Health Strategies, Bethesda, MD, USA

HEALTH CARE USE & POLICY STUDIES - Quality of Care
PHP119
WITHDRAWN

HEALTH CARE USE & POLICY STUDIES - Regulation of Health Care Sector
PHP120
G17
EXTERNAL REFERENCE PRICING (ERP) IN TURKEY AND ITS EFFECTS ON COUNTRIES THAT REFER TO TURKEY
Deger C, Ozdemir AZ, Sumer F, Parali E, Yilmaz ZS, Tunalioglu A, Ustunel B, Ozel MO
Bayer Turk Kimya San. Ltd. Sti., Istanbul, Turkey

PHP121
G18
DESCRIPTIVE REVIEW OF THE PHARMACOVIGILANCE AND RISK ASSESSMENT COMMITTEE (PRAC) ACTIVITIES SINCE ITS ESTABLISHMENT
Acquadro C1, Boxall N2, Maier W2
1Mapi Research Trust, Lyon, France, 2Mapi, London, UK

PHP122
WITHDRAWN

PHP123
G19
PERSPECTIVE OF SOCIAL PARTICIPATION IN THE EVALUATION PROCESS OF INCORPORATING TECHNOLOGY IN HEALTHCARE
Chacarolli CF1, Silveira LC1, Rabelo R1, Gonçalves H1, Vidal JR1, Gandara PM1, Biella C1, Santos VC1, Petramale C2
1Brazilian Ministry of Health, Brasília-DF, Brazil, 2Ministry of Health, Brasília-DF, Brazil

PHP124
WITHDRAWN

PHP125
G20
HIGH-COST MEDICINES IN BRAZIL: CENTRALIZED PURCHASE FOR OPTIMIZATION OF BUDGETARY RESOURCES AND INCREASING ACCESS IN THE PUBLIC HEALTH SYSTEM
Alexandre RF, Schneiders RE, Xavier LC, Barros SC, Nascimento Junior JM, Gadelha CA
Brazilian Ministry of Health, Brasília, Brazil

HEALTH CARE USE & POLICY STUDIES - Conceptual Papers
PHP126
WITHDRAWN

PHP127
G21
PRAGMATIC MCDA COMBINED WITH ADVANCED PHARMACOEPIDEMIOLOGY FOR QUANTITATIVE BENEFIT/RISK ASSESSMENTS OF MEDICINES
Goetghebeur M1, Timmaraju V2, Bec M3, Wagner M1, Micaleff A4, Amzal B2
1LASER Analytica, Montreal, QC, Canada, 2LASER Analytica, London, UK, 3LASER Analytica, Paris, France, 4MerckSerono SA, Eysins, Switzerland

PHP128
H1
ASSESSING THE IMPACT OF A MULTI-MILLION PUBLIC-PRIVATE PARTNERSHIP FOR TRANSLATIONAL RESEARCH: THE CENTRE FOR TRANSLATIONAL MOLECULAR MEDICINE (CTMM)
Steuten LM1, Schutten M2, Kip M2, IJzerman MJ1
1University of Twente, Enschede, The Netherlands, 2PANAXEA bv, Enschede, The Netherlands

PHP129
H2
HOW TO CONSIDER EQUITY IN DECISIONS TO INCORPORATE NEW TECHNOLOGIES IN BRAZILIAN UNIFIED HEALTH SYSTEM (SUS)?
Pereira VC1, Silva E2, Biella C1, Santos VC1, Petramale C1
1Brazilian Ministry of Health, Brasília-DF, Brazil, 2Brasília University, Brasília, DF, Brazil

PHP130
H3
THE RELEVANCE OF HEALTH TECHNOLOGY ASSESSMENT OF DIAGNOSTIC, PROGNOSTIC AND PREDICTIVE TESTS IN ONCOLOGY. PROSPECTS FOR IMPLEMENTATION IN RUSSIA
Yagudina R, Sorokovikov I
I.M. Sechenov First Moscow State Medical University, Moscow, Russia

PHP131
H4
QUANTIFYING THE VALUE OF TRANSITIONAL CARE PHARMACY SERVICES
Szesny D
University of Kentucky, Lexington, KY, USA

PHP132
H5
PHARMACEUTICAL PAYMENT REFORM OF TAIWAN, NHI
Shin-I C, Shu-Cheng L
Ministry of Health and Welfare, Taiwan, R.O.C, Taipei City,Taiwan (R.O.C.), Taiwan

PHP133
H6
CONCEPTUAL FRAMEWORK CHARACTERIZING NEUROCOGNITIVE BURDEN ASSOCIATED WITH PRIMARY GLIOBLASTOMA PROGRESSION
Bartley K, Theodore-Oklota C, Campbell A
Genentech, South San Francisco, CA, USA

PHP134
H7
EVIDENCE BASED APPROACH TO EVALUATE AND IMPROVE ACCESS TO MEDICINES IN EMERGING MARKETS
Shankar R1, Hickson S1, Sabat A2
1IMS Consulting Group, Cambridge, UK, 2IMS Consulting Group, Mumbai, India

PHP135
H8
THE INFLUENTIAL PATIENT: ROLE OF PATIENT OPINION LEADERS ON PHARMACEUTICAL RESEARCH AND DEVELOPMENT, HEALTH POLICY, AND COMMERCIALIZATION
Ko J1, Godley PJ2
1Scott & White Health Plan/Univ of Texas at Austin/Novartis Pharmaceuticals Corp., Temple, TX, USA, 2Scott & White Health Plan, Temple, TX, USA

PHP136
H9
COMPARATIVE ANALYSIS OF THE LSHT SECTOR CONCERNING WEALTH CREATION AND ECONOMIC GROWTH FOR SELECTED LSHT SUB-SECTORS IN SELECTED CANADIAN PROVINCES AND US STATES AS WELL AS EUROPEAN REGIONS
Savoie M1, Denis D2, Ouimet N3
1University of Montreal, Montreal, QC, Canada, 2KPMG-SECOR, Montreal, QC, Canada, 3Montreal InVivo, Montreal, QC, Canada

PHP137
H10
TRANSFERABILITY OF INTERNATIONAL EVIDENCE ON THE BENEFITS OF INNOVATIVE MEDICINES INTO CENTRAL EASTERN EUROPEAN COUNTRIES
Inotai A1, Kalo Z2, Petrova G3, Vitezic D4
1Syreon Research Institute, Budapest, Hungary, 2Eötvös Loránd University (ELTE), Budapest, Hungary, 3Medical University Sofia, Faculty of Pharmacy, Sofia, Bulgaria, 4University of Rijeka Medical School and University Hospital Centre Rijeka, Rijeka, Croatia

PHP138
H11
MENTAL HEALTH LITERACY THEORY: A CRITICAL EVALUATION
Bamgbade BA1, Harrision TC2, Barner JC1
1The University of Texas at Austin, College of Pharmacy, Austin, TX, USA, 2The University of Texas at Austin, School of Nursing, Austin, TX, USA

PHP139
H12
EXAGGERATED EXPIRATION DATES OF PHARMACEUTICALS: ENHANCING ECONOMIC BURDEN ON HEALTH CARE SYSTEM OF A COUNTRY
Kaushal N, Vaidya Y, Gulati M, Singh SK
Lovely Professional University, Phagwara, India

PHP140
H13
THE DIGITAL DIVIDE: CHALLENGING ASSUMPTIONS TO IDENTIFY THE IMPORTANCE OF A TAILORED APPROACH FOR ADHERENCE AND PATIENT ENGAGEMENT
McKay C
Merck & Co., Inc., North Wales, PA, USA

PHP141
H14
THE IMPORTANCE OF HTA TO SUBSIDIZE THE JUDICIALIZATION OF HEALTH
Patterson I
BRAZILIAN MINISTRY OF HEALTH, BRASILIA, Brazil

PHP142
H15
THE IMPACT OF THE ASEAN COMMUNITY AND THAILAND'S MEDICAL HUB ASPIRATION ON THE THAI HEALTH CARE SYSTEM
Rojanasarot S
University of Minnesota, Minneapolis, MN, USA

PHP143
H16
MULTI CRITERIA DECISION ANALYSIS METHODS IN HEALTH CARE: CURRENT STATUS, GOOD PRACTICE AND FUTURE RECOMMENDATIONS
Thokala P1, Marsh K2, Devlin N3, van Til J4, Reddy B5, Baltussen R6, IJzerman MJ7
1University of Sheffield, Sheffield, UK, 2Evidera, London, UK, 3Office of Health Economics, London, UK, 4University of Twente, Enschede, The Netherlands, 5National Centre for Pharmacoeconomics, Dublin, Ireland, 6Radboud University, Nijmegen, Gelderland, The Netherlands, 7University of Twente and MIRA institute for Biomedical Technology & Technical Medicine, Enschede, The Netherlands

PHP144
H17
PERSONALIZED DRUG DEVELOPMENT: STRATEGIC AND OPERATIONAL INSIGHTS FOR BIOPHARMA, PAYERS AND PROVIDERS FROM A LARGE SURVEY OF US AND EU DECISION MAKERS
Hoschander S1, Doyle J2, Istas A3, Faulkner EC4
1Quintiles Consulting, Hawthorne, NY, USA, 2Quintiles Global Consulting, Hawthorne, NY, USA, 3Quintiles, Durham, NC, USA, 4Institute for Pharmacogenomics and Individualized Therapy, Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, NC, USA

PHP145
H18
PREDICTING PRICE-TO-CHARGE RATIOS FOR COMMUNITY HOSPITALS IN THE UNITED STATES
Smith M1, Karaca Z2, Wong H2
1Truven Health Analytics, Bethesda, MD, USA, 2Agency for Healthcare Research and Quality (AHRQ), Rockville, MD, USA

PHP146
H19
NUTRITION PHARMACO-ECONOMICS: SPECIFICITIES AND CHALLENGES
Amzal B1, Chevrou-Severac H2
1LASER Analytica, London, UK, 2Nestlé Health Science, Vevey, Switzerland

PHP147
H20
A SYSTEMS-THINKING APPROACH FOR THE HEALTHCARE INDUSTRY: AN ATTITUDINAL SURVEY OF BIOPHARMA, PAYERS AND PROVIDER STAKEHOLDERS
Hoschander S1, Doyle J2, Istas A3
1Quintiles Consulting, Hawthorne, NY, USA, 2Quintiles Global Consulting, Hawthorne, NY, USA, 3Quintiles, Durham, NC, USA

Contact ISPOR @ info@ispor.org | View Legal Disclaimer
© 2018 International Society for Pharmacoeconomics and Outcomes Research.
All rights reserved under International and Pan-American Copyright Conventions.